Astellas Loses U.S. Court Case To Block Generic Versions Of Prograf Drug
This article was originally published in PharmAsia News
Astellas Pharma said its legal fight to block U.S. FDA approval of generic versions of its Prograf (tacrolimus) transplant drug has been rejected by a U.S. District Court. Astellas said it was reviewing its options, which could include an appeal to a higher court to require the FDA to demand higher prescribing standards for the generics. Astellas also lost a request for a preliminary injunction against further FDA approvals. Just days earlier, the FDA approved a Novartis generic version of Prograf. (Click here for more - a subscription may be required
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Comments ahead of the vaccine advisory committee ranged from public health groups opposed to emergency use authorizations, to industry requests for guidance on EUA labeling materials.
"One of the issues that COVID-19 has brought out is, how safe is the production of animal-based food products?"